Synageva BioPharma and Trimeris Announce Special Meetings of Stockholders to Approve Merger
13 Octubre 2011 - 7:00AM
Business Wire
Synageva BioPharma Corp. (“Synageva”), and Trimeris, Inc.
(NASDAQ: TRMS) (“Trimeris”), announced today that each company will
hold a special meeting of its stockholders on Wednesday, November
2, 2011, to consider and vote on certain matters in connection with
the proposed merger of Synageva and Trimeris, pursuant to the
Agreement and Plan of Merger, dated June 13, 2011. The Board of
Directors and Special Committees for both Synageva and Trimeris
have recommended approval of the merger and encourage stockholders
to vote “FOR” the respective proposals of each company as set forth
in the proxy statement. Synageva and Trimeris have set the close of
business on September 23, 2011 and September 21, 2011,
respectively, as the record date for the determination of their
respective stockholders entitled to vote at their respective
special meetings of stockholders.
(Photo: Business Wire)
Synageva and Trimeris stockholders are encouraged to read the
definitive proxy statement in its entirety as it provides, among
other things, a detailed discussion of the process that led to the
proposed merger.
About Synageva BioPharma Corp.
Synageva is a clinical stage biopharmaceutical company focused
on the discovery, development, and commercialization of therapeutic
products for patients with life-threatening rare diseases and unmet
medical need. SBC-102 has been granted orphan designations by the
U.S. Food and Drug Administration (“FDA”) and the European
Medicines Agency, and fast track designation by the FDA. Synageva
has several protein therapeutics in its pipeline, including two
enzyme replacement therapies for lysosomal storage disorders and
two programs for life-threatening genetic conditions for which
there are currently no approved treatments. The company has
assembled a team with a proven record of bringing orphan therapies
to patients.
On June 13, 2011, Synageva announced that it had entered into a
definitive agreement pursuant to which Synageva will merge with
Trimeris, Inc. (NASDAQ: TRMS) in an all-stock transaction. Upon
closing, the combined company will be named Synageva BioPharma
Corp., and will create a publicly-traded company focused on the
development of novel therapeutics for patients with rare diseases
and unmet medical need.
Further information regarding Synageva BioPharma Corp. is
available at http://www.synageva.com.
About Trimeris, Inc.
Trimeris, Inc. (NASDAQ: TRMS) pioneered the development of a
class of antiviral drug treatments called fusion inhibitors.
Trimeris’ currently marketed product is FUZEON, an anti-HIV fusion
inhibitor which was developed by Trimeris in collaboration with
Roche. Substantially all of Trimeris' revenues are derived from its
collaboration with Roche relating to FUZEON. For more information
about Trimeris, please visit the company's website at
http://www.trimeris.com.
Important Merger Information and Additional Information and
Where to Find It
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any securities of Trimeris or
Synageva or the solicitation of any vote or approval. In connection
with the proposed merger, Trimeris filed with the Securities and
Exchange Commission (“SEC”), and the SEC has declared effective, a
Registration Statement on Form S-4 that includes a joint proxy
statement/prospectus of Synageva and Trimeris and that also
constitutes a prospectus of Trimeris. The definitive joint proxy
statement of Trimeris and Synageva has been mailed to the
stockholders of Trimeris and the stockholders of Synageva.
Investors are strongly urged to read the definitive joint proxy
statement/prospectus regarding the proposed merger and other
documents filed with the SEC by Trimeris, because they contain
important information about Trimeris, Synageva and the proposed
merger.
Investors and security holders of Trimeris and Synageva may
obtain free copies of the definitive joint proxy
statement/prospectus for the proposed merger and other documents
filed with the SEC by Trimeris through the website maintained by
the SEC at www.sec.gov. In addition, investors and security holders
of Trimeris will be able to obtain free copies of the joint proxy
statement/prospectus for the proposed merger by directing a request
for such filing to (i) Trimeris, Inc., 2530 Meridian Parkway, 2nd
Floor, Durham, North Carolina 27713, Attention: Corporate Secretary
or (ii) Trimeris’ proxy solicitor, MacKenzie Partners, Inc., 105
Madison Avenue, New York, New York 10016, or by calling MacKenzie
Partners, Inc. at (800) 322-2885 (toll free) or(212) 929-5500 (call
collect). Investors and security holders of Synageva will be able
to obtain free copies of the joint proxy statement/prospectus for
the merger by contacting Synageva BioPharma Corp., Attn: Secretary,
128 Spring Street, Suite 520, Lexington, MA 02421.
Trimeris and Synageva, and their respective directors and
certain of their executive officers, may be deemed to be
participants in the solicitation of proxies in respect of the
transactions contemplated by the agreement between Trimeris and
Synageva. Information regarding Trimeris’ directors and executive
officers is contained in Trimeris’ Annual Report on Form 10-K for
the fiscal year ended December 31, 2010, which was filed with the
SEC on March 14, 2011, and in its proxy statement prepared in
connection with its 2010 Annual Meeting of Stockholders, which was
filed with the SEC on March 16, 2010. Information regarding
Synageva’s directors and officers and a more complete description
of the interests of Trimeris’ and Synageva’s respective directors
and officers in the proposed transaction is available in the
definitive joint proxy statement/prospectus of Trimeris and
Synageva filed by Trimeris with the SEC on October 12, 2011.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50027791&lang=en
Trimeris (NASDAQ:TRMS)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Trimeris (NASDAQ:TRMS)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024